[{"orgOrder":0,"company":"Alcon Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Inc \/ OcuMension Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Dextran 70

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                          Product Name : Tears Naturale Forte

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 08, 2024

                          Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : OcuMension Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          University of Birmingham

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Birmingham

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : ILB

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          October 15, 2018

                          Lead Product(s) : Dextrans

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Tikomed | University Hospital Birmingham | Neuregenix

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : ILB

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          August 03, 2018

                          Lead Product(s) : Dextrans

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sunnybrook Health Sciences Centre

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 17, 2012

                          Lead Product(s) : Dextrans

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Defence Research and Development Canada

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank